April 22nd, 2013
In recent years the FDA has come under increasing fire for approving drugs on the basis of surrogate endpoints without any evidence of greater clinical benefit. The most famous example of this is the diabetes drug rosiglitazone. Despite strong evidence demonstrating that it was effective at lower blood glucose levels — the surrogate endpoint — serious questions […]
May 7th, 2012
Brahmajee Nallamothu puts into context the most recent study on the value of measuring the progression of carotid intima-media thickness.